Literature DB >> 11531969

Identification of fifteen novel mutations and genotype-phenotype relationship in Fabry disease.

G M Altarescu1, L G Goldfarb, K Y Park, C Kaneski, N Jeffries, S Litvak, J W Nagle, R Schiffmann.   

Abstract

Fabry disease is an X-linked recessive disorder caused by a deficiency in the lysosomal enzyme alpha-galactosidase A, which results in a progressive multisystem disease. Most families have private mutations and no general correlation between genotype and disease manifestations has been described to date. Forty-nine patients (47 males and 2 females) from 36 affected families were selected for the study. Their evaluation included clinical examination, identification of alpha-galactosidase A gene mutations and residual enzymatic activity. For mutation detection, each exon with flanking intronic sequences was amplified by polymerase chain reaction (PCR) from the patient's genomic DNA and sequenced. Analysis of the resulting sequences was conducted to identify structural defects in the gene. Each of the Fabry patients carried a mutation in the alpha-galactosidase A gene. Fifteen mutations were novel. They included missense mutations (M51K, Y123M, G261D), nonsense point mutations (E251X) and small insertions or deletions creating a premature translational termination signal (P6X, D93X, W162X, K240X, H302X, I303X, L403X, S345X, G375X, F396X). Residual alpha-galactosidase A activity was significantly lower in patients with neuropathic pain (p=0.01) and in patients with mutations leading to a nonconservative amino acid change (p=0.04). Our findings emphasize the wide variety of genetic mechanisms leading to Fabry disease. A significant genotype-phenotype relationship was found.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11531969     DOI: 10.1034/j.1399-0004.2001.600107.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  16 in total

1.  Hearing loss in adult patients with Fabry disease treated with enzyme replacement therapy.

Authors:  Eefje B Suntjens; Bouwien E Smid; Marieke Biegstraaten; Wouter A Dreschler; Carla E M Hollak; Gabor E Linthorst
Journal:  J Inherit Metab Dis       Date:  2014-11-14       Impact factor: 4.982

2.  Fabry disease: correlation between structural changes in alpha-galactosidase, and clinical and biochemical phenotypes.

Authors:  Fumiko Matsuzawa; Sei-ichi Aikawa; Hirofumi Doi; Toshika Okumiya; Hitoshi Sakuraba
Journal:  Hum Genet       Date:  2005-05-28       Impact factor: 4.132

3.  Effective clearance of GL-3 in a human iPSC-derived cardiomyocyte model of Fabry disease.

Authors:  Jean-Michel Itier; Gwénaëlle Ret; Sandra Viale; Lindsay Sweet; Dinesh Bangari; Anne Caron; Françoise Le-Gall; Bernard Bénichou; John Leonard; Jean-François Deleuze; Cécile Orsini
Journal:  J Inherit Metab Dis       Date:  2014-05-22       Impact factor: 4.982

Review 4.  Enzyme replacement therapy and beyond-in memoriam Roscoe O. Brady, M.D. (1923-2016).

Authors:  Markus Ries
Journal:  J Inherit Metab Dis       Date:  2017-03-17       Impact factor: 4.982

5.  A novel 6 bp insertion in exon 7 associated with an unusual phenotype in a family with Fabry disease.

Authors:  Th Kroepfl; K Paul; P Kotanko; B Plecko; E Paschke
Journal:  J Inherit Metab Dis       Date:  2002-12       Impact factor: 4.982

6.  Neuropathic and cerebrovascular correlates of hearing loss in Fabry disease.

Authors:  M Ries; H J Kim; C K Zalewski; M A Mastroianni; D F Moore; R O Brady; J M Dambrosia; R Schiffmann; C C Brewer
Journal:  Brain       Date:  2006-11-14       Impact factor: 13.501

7.  ACE activity is modulated by the enzyme α-galactosidase A.

Authors:  Elice Carneiro Batista; Luiz Roberto Carvalho; Dulce Elena Casarini; Adriana Karaoglanovic Carmona; Edson Lucas dos Santos; Elton Dias da Silva; Robson Augusto dos Santos; Clovis Ryuichi Nakaie; Maria Verônica Munoz Rojas; Suzana Macedo de Oliveira; Michael Bader; Vânia D'Almeida; Ana Maria Martins; Kely de Picoly Souza; João Bosco Pesquero
Journal:  J Mol Med (Berl)       Date:  2010-10-13       Impact factor: 4.599

8.  Structure-function relationships in alpha-galactosidase A.

Authors:  Scott C Garman
Journal:  Acta Paediatr       Date:  2007-04       Impact factor: 2.299

Review 9.  Fabry's disease: an example of cardiorenal syndrome type 5.

Authors:  Aashish Sharma; Marco Sartori; Jose J Zaragoza; Gianluca Villa; Renhua Lu; Elena Faggiana; Alessandra Brocca; Luca Di Lullo; Sandro Feriozzi; Claudio Ronco
Journal:  Heart Fail Rev       Date:  2015-11       Impact factor: 4.214

10.  A Novel Frameshift Mutation of Galactosidase-alpha in Fabry Disease Restricted to Dermatologic Manifestations.

Authors:  Dae Hun Kim; Soo Yeon Kim; Myung Im; Young Lee; Young Joon Seo; Jeung Hoon Lee
Journal:  Ann Dermatol       Date:  2013-02-14       Impact factor: 1.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.